Linda Stein Gold, EADV 2020 – Roflumilast Cream in Chronic Plaque Psoriasis
We caught up with Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to discuss the results of the phase 2B study of roflumilast cream in adults with chronic plaque psoriasis (ClinicalTrials.gov identifier: NCT03638258).
Questions
1. What are the limitations of current topical therapies for chronic plaque psoriasis? (0:06)
2. What is the mechanism of action of roflumilast and what are its advantages compared with other PDE4 inhibitors used in dermatology? (1:03)
3. Could you tell us a little about the ARQ-151 201 study and its efficacy and safety findings? (1:47)
4. Tell us more about the effect of roflumilast on patient-reported outcomes. (2:48)
5. What were the limitations of this study and what future studies are planned? (3:49)
Disclosures: Dr Gold Stein reports the following relationships – Arcutis: Investigator, Advisor; Dermavant: Investigator, Advisor; Leo Pharma: Investigator, Advisor; Ortho Derm: Investigator, Advisor; and Pfizer: Investigator, Advisor, Speaker.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the EADV 2020 Virtual Congress.
